Sutekast 12.5 mg Capsules contain Sunitinib Malate, a targeted anti-cancer therapy used in oncology treatment protocols under strict medical supervision. It belongs to the tyrosine kinase inhibitor (TKI) class of medicines used in the management of specific cancers.
City Drug Exporters supplies high-quality, regulated pharmaceutical products for international export markets through compliant and licensed distribution channels.
1.Absorption: Sunitinib is absorbed well following oral administration. Maximum plasma concentrations are generally reached within 6 to 12 hours post-dose.
2.Distribution: Sunitinib and its primary active metabolite show high binding to human plasma protein, at 95% and 90% respectively.
3.Metabolism: Sunitinib is metabolized primarily by the cytochrome P450 enzyme CYP3A4 into its primary active metabolite (SU012662), which is also further metabolized by the same enzyme.
4.Elimination: The primary route of elimination is through feces (61% of the dose), while renal elimination accounts for 16% of the administered dose.
5.Half-Life: Following single oral doses, the terminal half-life of sunitinib is 40 to 60 hours, and the active metabolite is 80 to 110 hours.
6. Steady-State: Steady-state plasma levels are typically achieved within 10 to 14 days of continuous daily dosing.
Why Choose City Drug Exporters ?
Reliable pharmaceutical export sourcing.
Strong global supply network.
Quality-controlled products.
Documentation support for export compliance.
Timely international delivery coordination.
